24) For the first time, this study provides evidence that RANKL expression in OSCC might be associated with disease recurrence and a cell compartment measured by CD44+/RANKL+ co-expression within the mucosal epithelial basal layer cells. |
PMID:23979059 DOI:10.1007/s10266-013-0133-2 |
2015 Odontology |
* Co-expression of CD44+/RANKL+ tumor cells in the carcinogenesis of oral squamous cell carcinoma. |
- Receptor activator of nuclear factor-kappa (RANK)/receptor activator of nuclear factor-kappa B ligand (RANKL) signaling helps putative cancer stem cells (CSC) to maintain their stemness. Expression of CD44 and RANKL was analyzed in oral squamous cell carcinoma specimen (n = 191). Moreover, RANKL expression was measured in cancer cell lines (BICR3, BICR56) by immunohistochemistry and western blot analysis. Scanned images were digitally analyzed using ImageJ and the immunomembrane plug-in. CD44 and RANKL expression on protein level was correlated with clinical characteristics and impact on survival. RANKL was co-labeled with CD44 in immunohistochemical and immunofluorescence double labeling experiments. Although high CD44+/RANKL+ co-expression was significantly associated with clinicopathological factors and worse survival, multivariate analysis did not demonstrate high CD44+/RANKL+ co-expression as independent prognostic factor. Immunohistochemical and immunofluorescence double labeling experiments revealed RANKL expression by CD44+ cancer cells. RANKL specificity was confirmed by western blot analysis. For the first time, this study provides evidence that RANKL expression in OSCC might be associated with disease recurrence and a cell compartment measured by CD44+/RANKL+ co-expression within the mucosal epithelial basal layer cells. |
(1)80 *null* | (15)5 as | (29)3 exposed | (43)2 expanded |
(2)47 and | (16)5 expressed | (30)3 have | (44)2 expressing |
(3)39 were | (17)5 of | (31)3 isolated | (45)2 had |
(4)26 in | (18)5 which | (32)3 showed | (46)2 labeled |
(5)12 (MSCs) | (19)4 (ASCs) | (33)3 we | (47)2 may |
(6)11 was | (20)4 has | (34)2 (ASCs), | (48)2 play |
(7)10 to | (21)4 is | (35)2 (BMSCs) | (49)2 present |
(8)9 with | (22)4 on | (36)2 (ECFCs) | (50)2 remains |
(9)7 are | (23)4 seeded | (37)2 (HSCs) | (51)2 such |
(10)6 can | (24)4 within | (38)2 after | (52)2 the |
(11)6 for | (25)3 (ASC) | (39)2 by | (53)2 via |
(12)6 from | (26)3 (ECs) | (40)2 caused | |
(13)6 or | (27)3 (HUVECs) | (41)2 cultured | |
(14)6 that | (28)3 (hMSCs) | (42)2 derived |
add keyword